Fundraising FoxMarin Sonoma Impact Ventures — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Lighthouse Pharmaceuticals develops precision therapeutics for major unmet medical needs, with a lead program (LHP588), a gingipain inhibitor being tested in the Phase 2 SPRING trial for P. gingivalis-positive Alzheimer's disease.
BiotechLongevityNovato, US
Casey Lynch(Executive Officer, Director, Promoter)inStephen Dominy(Director)
BoardCampbell Murray(Director)in
Spindl provides attribution, analytics, audience-building, and advertising tools for onchain (crypto/Web3) applications, letting teams track user journeys from web clicks to onchain actions across chains.
AdTechCrypto & Web3Marketing Tech
Jon Wienner(Founder)in
Co-investorsBankless VenturesCoinbase VenturesConsenSys MeshFJ LabsMulticoin Capital7percent Ventures+15 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.